This study is currently not recruiting participants.

Prospective Multicenter Single-arm Study to Evaluate Efficacy Safety and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta

Study of Investigational Medication in Children with Osteogenesis Imperfecta

Not Recruiting
100 years or below
All
Phase N/A

Brief description of study.

The purpose of this study is to find out more about denosumab in children with osteogenesis imperfecta.

Detailed description of study

The purpose of this study is to find out more about denosumab in children with osteogenesis imperfecta.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: osteogenesis imperfecta
  • Age: 100 years or below
  • Gender: All

This study investigates the effects of an investigational medication in children with osteogenesis imperfecta, a genetic disorder that affects bone strength and causes bones to break easily. The purpose of this study is to learn more about how the investigational medication can impact bone health in these children.

Participants in the study will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine. The study will involve regular monitoring and assessments to evaluate the medication's effect on bone health.

  • Who can participate: Children aged X-Y with osteogenesis imperfecta.
  • Study details: Participants will be randomly assigned to receive either the investigational medication or a placebo. They will be monitored regularly to assess the effects on bone health.
Updated on 19 Feb 2024. Study ID: 1411799216

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team